Enhertu Beats Chemo-Immunotherapy in First-Line HER2-Mutant Lung Cancer

AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo said Enhertu (trastuzumab deruxtecan) met its primary endpoint in DESTINY-Lung04, the Phase 3 trial testing the antibody-drug conjugate as a first-line treatment for HER2-mutant non-small cell lung cancer (NSCLC). AstraZeneca closed at $164.49 on August 20; Daiichi Sankyo’s ADR closed at $18.04.

In the August 17 readout, Enhertu showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus the global standard of care, platinum-pemetrexed chemotherapy plus pembrolizumab. The companies did not disclose the hazard ratio, and the trial will continue to evaluate overall survival and other secondary endpoints.

The result makes Enhertu the first and only HER2-directed medicine to improve PFS over standard of care in a Phase 3 trial in the first-line setting. HER2 mutations appear in about 2% to 4% of NSCLC cases, often in younger women with no smoking history, and the mutation is tied to poor prognosis and a higher rate of brain metastases.

Why It Matters

Enhertu is already approved for previously treated HER2-mutant NSCLC, an indication built on the DESTINY-Lung02 and DESTINY-Lung05 trials. DESTINY-Lung04 is the confirmatory study aimed at moving the drug into the first-line setting, where the current standard is chemo-immunotherapy and no HER2-targeted option exists.

Moving Enhertu earlier in treatment expands its addressable population and cements its position as the category leader in HER2-mutant lung cancer. The 454-patient trial is the largest head-to-head test of a HER2-directed ADC against first-line standard of care in this disease. For background on how Enhertu and its DXd payload technology work, see our guide to antibody-drug conjugates and our analysis of Daiichi Sankyo’s ADC franchise.

The safety profile in DESTINY-Lung04 was consistent with Enhertu’s known profile, with no new safety signals identified.

What Happens Next

The companies will present detailed DESTINY-Lung04 data at a forthcoming medical meeting and share results with global regulators. The headline PFS win sets up a potential first-line label expansion, but investors will watch the overall survival readout, which remains immature. The first-line HER2-mutant NSCLC setting is a multi-billion-dollar opportunity that has lacked a targeted therapy until now.

What It Means for the Trade

The trade question is how much incremental revenue a first-line label adds, and the honest answer is: meaningful but not franchise-transforming. HER2 mutations run at 2-4% of NSCLC. Against roughly 1.8 million global NSCLC diagnoses a year (about 200,000-plus in the U.S.), that’s an addressable population in the low tens of thousands annually. What changes is the position within that population: first-line patients are treated longer, at higher per-patient revenue, and the current standard — pembrolizumab plus platinum-pemetrexed — delivers responses that rarely last. Displacing chemo-immunotherapy as the default in a biomarker-defined niche is exactly how Tagrisso built a multi-billion-dollar franchise in EGFR-mutant disease.

The PDUFA path is the near-term catalyst to mark. Expect an sBLA filing quickly given the confirmatory design, a decision likely inside 2026-2027, and then payer fights over sequencing. Also watch China: Enhertu is partnered separately, and HER2-mutant NSCLC trials from domestic players are coming — first-line share there is Daiichi’s to lose.

For the AZN/Daiichi relationship, the readout is strategically bigger than the revenue. Enhertu is the flagship of the companies’ multi-ADC collaboration, and every label expansion validates the DXd linker-payload platform that also carries Datalys-1 (TROP2, first-line NSCLC, competing with GSK’s Trodelvy ambitions) and multiple earlier-stage programs. One clean first-line win de-risks the platform narrative across the portfolio.

Mechanism and Market Context

Why an ADC beats chemo-immunotherapy here: HER2-mutant tumors are often “cold” to immunotherapy — the mutation enriches for never-smokers with low tumor mutational burden, so pembrolizumab contributes less than in typical NSCLC. Enhertu sidesteps immunity entirely: the anti-HER2 antibody homes to the mutant-expressing tumor, the cleavable linker releases membrane-permeable DXd payload inside and into neighboring cells (the bystander effect), and cell-cycle killing proceeds regardless of immune engagement. That’s also why the drug works on mutations that aren’t amplifications — kinase-domain mutations still traffic enough receptor to concentrate payload.

The competitive landscape matters for durability. First-line HER2-mutant NSCLC has no other approved targeted agent, but the field is converging on it: Rybrevant-based regimens, MET/HER3 ADCs (patritumab deruxtecan failed to convert in EGFR-mutant disease, a cautionary datapoint for the class), and pan-HER TKIs are all circling. Enhertu’s head start plus a clean Phase 3 against standard of care is a high bar for anyone to attack. The bigger threat is internal: interstitial lung disease. Enhertu’s boxed-warning pneumonitis/ILD risk sits around 10% in lung indications, and in a first-line population with curative-adjacent intent and longer treatment duration, ILD management is the commercial and regulatory fault line to watch.

Risks and What Could Go Wrong

OS is the headline risk. A PFS win without mature overall survival opens the door to the classic immuno-oncology critique — delaying progression isn’t the same as extending life, especially when control-arm patients can receive Enhertu or other ADCs at progression (crossover/sequencing can blunt the OS curve). If the final DESTINY-Lung04 OS readout shows only a trend, payers will push back on first-line use and keep the drug concentrated in later lines, capping the expansion’s value.

Execution risk is secondary but real: brain metastases. HER2-mutant NSCLC metastasizes to the brain at high rates, and intracranial activity determines real-world first-line credibility. DESTINY-Lung02 showed respectable CNS activity, but the Phase 3 intracranial PFS breakdown will be a slide investors actually read. Finally, don’t over-size the move: AZN and Daiichi are enormous companies, Enhertu already does billions across breast, gastric, and lung indications — this is a stock-level rounding error for AstraZeneca, though it carries more weight at Daiichi, where Enhertu is the profit engine.